Syndax Pharmaceuticals, Inc.
NASDAQ Global SelectTotal Valuation
Syndax Pharmaceuticals, Inc. carries a market capitalization of 1.82B, placing it among publicly traded companies globally. Its enterprise value stands at 1.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.82B |
| Enterprise Value | 1.98B |
Share Statistics
Syndax Pharmaceuticals, Inc. currently has 89.15M shares outstanding.
| Shares Outstanding | 89.15M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 7.61, and the price-to-book ratio stands at 129.07.
| PE Ratio | N/A |
| PS Ratio | 7.61 |
| PB Ratio | 129.07 |
| P/TBV Ratio | 129.07 |
| P/FCF Ratio | -8.71 |
| P/OCF Ratio | -8.70 |
Enterprise Valuation
| EV / Sales | 7.86 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Syndax Pharmaceuticals, Inc. maintains a current ratio of 6.77, meaning it holds 6.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3,903.45, indicating elevated leverage, while an interest coverage ratio of -4.58 demonstrates limited ability to service its debt obligations.
| Current Ratio | 6.77 |
| Quick Ratio | 6.29 |
| Debt / Equity | 3,903.45 |
| Debt / EBITDA | -3.04 |
| Interest Coverage | -4.58 |
Financial Efficiency
| Return on Equity (ROE) | -255.93 |
| Return on Assets (ROA) | -33.97 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.42 |
Stock Price Statistics
Syndax Pharmaceuticals, Inc.'s stock has gained approximately 26.99197% over the past 52 weeks. The 50-day moving average sits at 20.93, while the 200-day moving average is 20.96.
| Beta (5Y) | N/A |
| 52-Week Price Change | 26.99197% |
| 50-Day Moving Average | 20.93 |
| 200-Day Moving Average | 20.96 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Syndax Pharmaceuticals, Inc. generated 252.25M in revenue and converted that into -220.76M in net income, yielding earnings per share of -2.51. EBITDA reached -194.16M, while operating income came in at -194.17M.
| Revenue | 252.25M |
| Gross Profit | 241.60M |
| Operating Income | -194.17M |
| Pretax Income | -220.76M |
| Net Income | -220.76M |
| EBITDA | -194.16M |
| EBIT | -194.17M |
| Earnings Per Share (EPS) | -2.51 |
Balance Sheet
Syndax Pharmaceuticals, Inc. holds 554.27M in cash and equivalents against 589.38M in total debt, resulting in a net debt position of 251.64M. Total book value stands at 15.10M, with working capital of 575.36M providing operational flexibility.
| Cash & Cash Equivalents | 554.27M |
| Total Debt | 589.38M |
| Net Debt | 251.64M |
| Equity (Book Value) | 15.10M |
| Book Value Per Share | 0.17 |
| Working Capital | 575.36M |
Cash Flow
Syndax Pharmaceuticals, Inc. produced -220.64M in operating cash flow over the past twelve months. After subtracting -187,000.00 in capital expenditures, free cash flow totaled -220.83M - equivalent to -2.51 per share.
| Operating Cash Flow | -220.64M |
| Capital Expenditures | -187,000.00 |
| Free Cash Flow | -220.83M |
| FCF Per Share | -2.51 |
Margins
Syndax Pharmaceuticals, Inc. operates with a gross margin of 95.78, reflecting its pricing power and cost economics. The operating margin of -76.98 and net profit margin of -87.52 provide insight into operational efficiency.
| Gross Margin | 95.78 |
| Operating Margin | -76.98 |
| Pretax Margin | -87.52 |
| Profit Margin | -87.52 |
| EBITDA Margin | -76.97 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -14.00 |
| FCF Yield | -11.49 |
Scores
Syndax Pharmaceuticals, Inc. posts an Altman Z-Score of -1.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.05 |